Primary endpoint met in RDX-002 trial to treat drug induced weight gain

[cafead]

via Response Pharmaceuticals has met the primary endpoint of a Phase Ib clinical trial of a first-in-class inhibitor, RDX-002, for the treatment of antipsychotic-induced weight gain.

article source